openPR Logo
Press release

Unmet Need Remains for Subcutaneous Sustained Release Injectables

09-13-2017 09:51 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) - As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration and reduced dosing frequency. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing.

While sustained release tablets and capsules continue to evolve, there are limitations to this approach to the dosing issue, and these limits have essentially been reached. This reality, and the fact that biological drugs cannot be delivered orally, have resulted in an accelerating interest in alternative modes of administration (MoA), a group that includes injection, inhalation and transdermal administration. Our analysis concludes that recent growth has been uneven across non-oral delivery segments, and that future prospects will be determined to a large degree by the ability of drug and device developers to address formulation and patient issues across the new drug landscape.

The leading beneficiary of current drug development pipelines and the move toward self-administration is the Injectable segment. The transition of Injectable drug packaging from vials to sophisticated and customized injection devices is accelerating at a time when caregiver and patient expectations continue to evolve. The result is an emerging set of de facto requirements for drug developers that often dictates the device strategy for a particular parental drug. This trend is strongly aligned within and around specific drug classes and is accelerating with each new Injectable that reaches the market.

Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating injectable formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

Large pharmaceutical and biotechnology companies are increasingly pursuing in-licensing to offset lower than expected drug development productivity and surging research costs. Data mining technologies, combined with data from genomics, combinational chemistry and outcome-based medicine, provide opportunities to search for new patterns. By using hypertext type tools, companies are finding it possible to build knowledge bases where scientists can link data and ideas to generate insights into new relationships between population groups, diseases, and treatment.

For sustained release formulations of Injectable drugs, development collaborations typically follow one of two business models. The majority of projects/products are marked by a contractual relationship between the formulation IP developer/holder and the drug developer. The second notable business model is more ambitious and is defined by formulation IP companies that develop sustained release formulations in-house before licensing the marketing rights to a partner, typically in late stage clinical development or after filing an NDA. This is a more powerful financial model, but has a higher level of risk and requires adequate capitalization to finance drug development into or up to Phase 3 trials.

A new report analyzes the current market and potential for extended release injectables. The report - Subcutaneous Sustained Release Injectables to 2024 - examines the therapeutic impact of approved SC sustained release injectable drugs and development-stage candidates, and analyzes key market segments, technology factors, demand drivers and the competitive landscape.

More information is available at www.greystoneassociates.org .



Source: Greystone Research Associates

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Unmet Need Remains for Subcutaneous Sustained Release Injectables here

News-ID: 712215 • Views: 248

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for Injectable

Global Specialty Injectable Generics Market Research Report
This report studies the global Specialty Injectable Generics market status and forecast, categorizes the global Specialty Injectable Generics market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Fresenius Mylan N.V. Teva Pharmaceutical Hikma Pharmaceuticals Novartis AG Uman Pharma Baxter Par Pharmaceutical
Global Injectable Drug Delivery Market to 2028 |Retail Pharmacies, Injectable Dr …
Market Research Hub (MRH) has carefully analyzed this research study titled Injectable Drug Delivery Market: Self-injectors to Remain Fastest Growing Product Type During the Forecast Period: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028, which is available on its online portal. The aim of this assessment is to highlight the various projections expected to occur in the global market for Injectable Drug Delivery. Readers can gain knowledge related to prime
Global and Chinese Sterile Injectable Drugs Market
https://www.qandqmarketresearch.com/reports/sterile-injectable-drugs2018-market-4 The Global and Chinese Sterile Injectable Drugs Industry, 2013-2023 Market Research Report is a professional and indepth study on the current state of the global Sterile Injectable Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Sterile Injectable Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report
Injectable Targeted Therapy Market: Primary application of injectable targeted t …
Targeted delivery is a clinical treatment used to deliver medication in patients to increase the concentration of medication in some parts of the body. Target specific drug delivery is localized, prolonged, targeted and have protected drug interaction with the diseased tissue. The advantage of injectable targeted therapy was the decrease in frequency of the dosages that are delivered to the patient, it more uniform effect of the drug, reduction of
Global Facial Injectable Market – Forecast, 2013-2021
Facial Injectable Market Wiseguyreports.Com Adds “Facial Injectable Market -Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Description: Facial Injectable products, also known as dermal fillers are products that help in trending applications such as bioengineering or facial rejuvenation. With age, facial skin is bound to lose subcutaneous fat naturally and
2017 - 2022: Injectable Targeted Therapy Global Market
Researchmoz added Most up-to-date research on "2017 - 2022: Injectable Targeted Therapy Global Market" to its huge collection of research reports. Targeted delivery is a clinical treatment used to deliver medication in patients to increase the concentration of medication in some parts of the body. Target specific drug delivery is localized, prolonged, targeted and have protected drug interaction with the diseased tissue. The advantage of injectable targeted therapy was the decrease